The failure last week of Biogen Inc. and Eisai Co.’s once-promising Alzheimer’s disease drug was the latest in a spate of disappointments for medicines designed to target Beta amyloid, a sticky substance long known to accumulate in the brains of people with the disease. The repeated failure of such drugs are giving greater currency to efforts by academics and smaller biotech companies to better understand the biology of Alzheimer’s and explore the use of drugs with alternative mechanisms of action. Some of the more promising...

Source: Wall Street Journal March 24, 2019 15:00 UTC